Latest News Archive

Please select Category, Year, and then Month to display items

Making mental health conversations trend

20 October 2022 | Story Valentino Ndaba | Photo Valentino Ndaba

The UFS community, in partnership with various stakeholders, commemorated World Mental Health Day on 10 October 2022.

About 400 million people globally suffer from mental or neurological disorders and psychosocial problems. Mental disorders, much like physical ones, differ in severity. The Department of Health distinguishes between transient (such as an acute stress disorder), periodic (such as bipolar disorder, characterised by periods of exaggerated elation followed by periods of depression), and long-lasting and progressive (such as Alzheimer’s disease) disorders.

Mental health issues such as depression, anxiety, substance abuse, and job stress are the most common conditions. It is not only the individuals suffering from these problems who are affected, but also their families, co-workers, and the broader community. An interplay between biological, psychological, social, and environmental factors results in mental health conditions.

Mobilising efforts in support of mental health
Internationally, the month of October has been declared Mental Health Awareness Month, with 10 October being the day on which Mental Health Day is observed. The objective is to educate the public about mental health and to reduce the stigma that people with mental illness are often subjected to. To mark the day, the University of the Free State (UFS) Student Counselling and Development (SCD) Office, KovsieHealth, and the student mental health advocacy organisation, Next Chapter, held an activation at the Thakaneng Bridge on the Bloemfontein Campus. This followed a silent walk from the campus’ main gate to the bridge.

Chairperson of Next Chapter, Lehlogonolo Sebjetseba, emphasised the significance of commemorating Mental Health Day. “The importance of observing this day is to continue raising awareness about mental health and to further reduce the stigma around mental health. We did this by introducing students to different psychosocial support organisations such as Alnisa Continua, Panda, the Befrienders, and more. These organisations cater specifically for students’ mental well-being,” said the second-year Industrial Psychology student.

Raise awareness of mental health issues
On 12 October 2022, the Division of Organisational Development and Employee Well-Being, together with the Department of Human Resources (HR), presented a Mental Health talk by award-winning journalist and author, Marion Scher, on the Bloemfontein Campus. The talk touched on preventive mental health interventions, breaking the silence around mental health issues, and guidelines on how to provide support to those affected by mental health problems.

Scher further explained bipolar disorder and schizophrenia, as well as the difference between a bad day and clinical depression. Guidance was provided on avenues to explore when seeking mental health assistance, and advice was offered on what to do if you think someone is having suicidal ideation. In addition, the division has made available the Mental Health Awareness Month Toolkit, which employees can access for free online.

Mental health is a global priority
The overall objective of World Mental Health Day is to raise awareness of mental health issues around the world. This year’s national theme is ‘Mental Health and Well-being for All: Promoting Mental Health in Physical and Virtual Spaces’, which is based on the global theme: ‘Making Mental Health and Well-Being for All a Global Priority’. This is in line with Sustainable Development Goal number three, which focuses on good health and well-being.

SCD and HR will continue to host events throughout the year that encourage students and staff to protect and improve their mental health. These are some of the upcoming events:

Health Survival Guide webinar (students):
Date: 21 October 2022
Time: 10:00
Venue: Blackboard

Self-care webinar (students):
Date: 1 November 2022
Time: 12:00-14:00
Venue: Blackboard

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept